VERACYTE INC (VCYT)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for VCYT
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| VCYT | $Former Chief Financial Officer, BioNTech SE; Director; Chair | 62 | ["Chief Financial Officer of BioNTech SE","Chief Financial Officer of MorphoSys AG","Various positions at Fresenius SE & Co. KGaA","Director of InflaRx N.V.","Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing","audit committee financial expert"] | ["Compensation","Audit","Audit (Chair)","Audit Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Jens Holstein has served on our Board of Directors since August 2020. From 2021 to 2025, Mr. Holstein served as Chief Financial Officer of BioNTech SE, a biotechnology company. Previously, Mr. Holstein served as Chief Financial Officer of MorphoSys AG, a biopharmaceutical company, from 2011 to 2020. From 1995 to 2011, Mr. Holstein held various positions at Fresenius SE & Co. KGaA, a healthcare company, including regional Chief Financial Officer of Fresenius Kabi AG for the EME (Europe/Middle East) region and managing director of Fresenius Kabi Deutschland GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London. Mr. Holstein served as a director of InflaRx N.V., a biopharmaceutical company, from 2018 to 2020 and on the Advisory Board of Mallia Therapeutics from July 2025 to February 2026. Mr. Holstein currently serves on the Advisory Board of Deutsche Bank AG since August 2024 and on the Advisory Board of Secarna Pharmaceuticals since January 2026. Mr. Holstein holds a diploma in Business Administration from the University of M nster, Germany. We believe that Mr. Holstein is qualified to serve on our Board of Directors due to his significant experience as the chief financial officer of a publicly traded biopharmaceutical company, as well as his extensive experience in management positions in life science and healthcare companies. Age: 62 Director Since: 2020 Committees: Audit (Chair) Compensation